Science you can understand. Quality you can verify.
Dr.Morgan+
Cart (0)
Products
Science
Learn
Professional

SCIENCE

Explore the science. Examine the context.

Begin with a question. Follow the information.

Explore ingredients, relevant research and the product information that connects them.

Explore evidence →
01

Ingredients

S-EQUOL PLUS · Ingredient example

Simplified pathway: daidzein is converted by certain gut bacteria to S-equol. Not everyone produces S-equol.
Fig. 1 — Simplified formation pathway. Conceptual illustration, not experimental data or a chemical structure. Intermediate steps are omitted.

What is S-equol?

S-equol is a metabolite that certain gut bacteria can form from daidzein, a precursor isoflavone. It is a different molecule from daidzein.

That conversion is not the same in everyone. Some people do not produce S-equol from daidzein.

Already formed.
Supplied directly.

Direct supplementation provides S-equol itself. Obtaining the supplemented S-equol does not require first converting daidzein into S-equol in the gut.

This distinction concerns the route to S-equol. It does not establish identical individual responses or superior clinical results.

Inside S-EQUOL PLUS
S-equol (synthetic) 10 mg + Genistein 16.7 mg AIE per capsule. Genistein is sourced from Glycine max (soybean) seed.

Licensed use: May reduce severe and frequent menopausal symptoms (such as hot flashes and/or night sweats).

For menopausal and postmenopausal women, 18 years and over. Read the directions, duration of use and warnings before use.

Explore S-EQUOL PLUSExplore the Women’s Midlife pathway

Know the formula.

S-EQUOL PLUS · NPN 80143622

S-equol · 10 mg per capsule
Source: synthetic S-equol. The formula provides S-equol directly.
Genistein · 16.7 mg AIE per capsule
Source: Glycine max (soybean) seed. AIE means aglycone isoflavone equivalents.

These are the medicinal ingredients. Consult the product label for the full ingredient list and directions.

S-equol and Genistein are listed separately. This product should not be described as soy-free.

From precursor to S-equol.

The gut conversion pathway

Daidzein is the starting precursor. Certain intestinal bacteria can convert it through intermediate steps into S-equol. The diagram simplifies this process; it does not mean that daidzein turns into bacteria.

Whether a person forms S-equol from daidzein varies. We do not attach a population percentage to this illustration.

What direct supplementation changes

Already-formed S-equol is supplied directly. This avoids relying on the initial daidzein-to-S-equol conversion to obtain that supplemented molecule. It does not mean that digestion, absorption or metabolism are unnecessary.

Our formula is not the same as the gut pathway

The product licence lists synthetic S-equol. This illustration explains biological formation; it is not a claim that the product is manufactured in the gut or that taking it changes the gut microbiome.

The formula also contains Genistein from Glycine max (soybean) seed. Genistein is a separate ingredient and is not shown here as the precursor to S-equol.

Sources & evidence context

Setchell et al., 2005 — S-equol formation and pharmacokinetics

Original study combining human samples, in-vitro bacterial conversion and a pharmacokinetic component in three adults. Ingredient/mechanism evidence, not a clinical efficacy trial of DR.MORGAN S-EQUOL PLUS.

Atkinson et al., 2004 — Variation in bacterial daidzein metabolism

In-vitro human faecal incubation study; supports discussion of conversion differences, not a finished-product efficacy claim.

Product facts: locally verified Health Canada product licence, NPN 80143622. The full licence text is available under Read the product licence.

Licensed product information

NPN 80143622 · EquoPro / S-EQUOL PLUS

Recommended use or purpose

May reduce severe and frequent menopausal symptoms (such as hot flashes and/or night sweats).

Medicinal ingredients per capsule

  • S-Equol — 10 mg. Source: S-Equol (Synthetic).
  • Genistein — 16.7 mg AIE. Source: Glycine max — Seed.

Recommended dose

Menopausal and postmenopausal women (18 years and over): 1 capsule, 1 time per day.

Take a few hours before or after taking other medications or health products.

Recommended duration of use

Ask a health care practitioner/health care provider/health care professional/doctor/physician for use beyond 1 year.

Use for at least 2 weeks to see beneficial effects.

Cautions and warnings

  • Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are not up-to-date on mammograms and gynaecological evaluations.
  • Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners or any hormone replacement therapy.
  • Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a liver disorder or a history of hormonal or gynaecological disease.
  • Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms worsen.

Contra-indications

Do not use if you have or had breast cancer or tumours or a predisposition to breast cancer, as indicated by an abnormal mammogram or biopsy, or a family member with breast cancer.

Known adverse reactions

Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if new symptoms develops such as breast pain, a recurrence of menstruation, uterine spotting or liver-related symptoms (e.g. abdominal pain, jaundice, dark urine).

Dosage form: Capsule, hard. Route: Oral.

Health Canada licence record

02

Research

Biological formation · simplified
DaidzeinPrecursor molecule
Conversion by certain gut bacteria
Varies between people
S-equolFormed metabolite
Fig. 2 — Conceptual pathway; intermediate steps omitted. Not a manufacturing process or experimental result.

Mechanistic research

Understanding S-equol starts with the original research. Laboratory studies help explain how certain gut bacteria form it from daidzein, and why conversion can differ between people.

These findings describe a biological pathway. Each study is presented with its methods, relevance and limitations so you can see what it contributes to the science.

S-EQUOL PLUS research example · Setchell 2005 / Atkinson 2004

Aso et al. · 2012 · Trial design
160participants randomized
Natural S-equol
10 mg / dayPlacebo
comparison
12 weeks126 participants completed
Fig. 3 — Design of a study using a different formulation. This is not a DR.MORGAN finished-product trial.

Clinical research

A randomized trial studied a natural S-equol preparation in postmenopausal Japanese women who did not produce equol. It reported a greater reduction in hot-flash frequency than placebo.

The preparation was different from S-EQUOL PLUS. Read the study design and population alongside its findings; ingredient evidence and our product licence answer different questions.

Selected ingredient evidence · not a systematic review

Three separate questions
Study typeHow was the study conducted?
Product relevanceWhat was actually studied?
Quality & limitationsWhat can the findings support?
Fig. 4 — Our evidence-reading framework. Separate dimensions, not a single strength ranking.

Read beyond the result.

A study’s design, its relevance to our formula, and its limitations each matter. We show these dimensions separately, alongside the population, duration and funding where available.

Mechanism research, ingredient trials and a product licence provide different kinds of information. The distinction stays visible when you open the original sources.

Read our product licence

How S-equol forms.

Selected research with its context. Study type, product relevance and limitations are shown separately.

Setchell et al. · 2005

Identifying S-equol and its formation

Study type
Mechanistic / analytical; human pharmacokinetic component
Relevance to DR.MORGAN
Mechanistic relevance
Sample / population
Pharmacokinetic component: 3 healthy adults
Duration
Single-dose pharmacokinetics; in-vitro formation experiments
Finding
Human samples and cultured intestinal flora supported S-equol formation from daidzein.
Limitations
Very small pharmacokinetic sample. Not a trial of menopausal symptom relief or of DR.MORGAN S-EQUOL PLUS.
Quality assessment
Methods and sample context reviewed from abstract; full risk-of-bias appraisal not completed.
Funding / conflicts
PubMed lists NIH support. Complete conflict disclosures not assessed here.
Read original study record

Atkinson et al. · 2004

Why conversion can differ between people

Study type
In-vitro human faecal incubation
Relevance to DR.MORGAN
Mechanistic relevance
Sample / population
Samples from 7 equol producers and 6 nonproducers
Duration
5-day laboratory incubation
Finding
The experiments examined differences in bacterial conversion of daidzein to equol.
Limitations
Laboratory model and small selected sample; does not measure symptom improvement or establish a population percentage.
Quality assessment
Abstract and original publication record reviewed; formal quality appraisal pending.
Funding / conflicts
Funding and conflicts not verified in this review.
Read original study record

Clinical evidence in context.

Selected research with its context. Study type, product relevance and limitations are shown separately.

Aso et al. · 2012

S-equol supplementation and hot flashes

Study type
Randomized, double-blind, placebo-controlled trial
Relevance to DR.MORGAN
Relevant ingredient evidence; different finished formulation
Sample / population
160 postmenopausal Japanese equol nonproducers randomized; 126 completed
Duration
12-week intervention
Finding
A natural S-equol preparation providing 10 mg/day showed a greater reduction in hot-flash frequency than placebo.
Limitations
The tested SE5-OH preparation differs from our synthetic S-equol plus Genistein formula. This is not a DR.MORGAN finished-product trial. Population, attrition and duration limit generalization.
Quality assessment
Primary methods, results and disclosures inspected; no formal overall risk-of-bias rating assigned.
Funding / conflicts
Otsuka supplied the preparation and funding; two authors reported consulting fees from Otsuka.
Read original study recordRead original full text

Licensed product information

NPN 80143622 · EquoPro / S-EQUOL PLUS

Recommended use or purpose

May reduce severe and frequent menopausal symptoms (such as hot flashes and/or night sweats).

Medicinal ingredients per capsule

  • S-Equol — 10 mg. Source: S-Equol (Synthetic).
  • Genistein — 16.7 mg AIE. Source: Glycine max — Seed.

Recommended dose

Menopausal and postmenopausal women (18 years and over): 1 capsule, 1 time per day.

Take a few hours before or after taking other medications or health products.

Recommended duration of use

Ask a health care practitioner/health care provider/health care professional/doctor/physician for use beyond 1 year.

Use for at least 2 weeks to see beneficial effects.

Cautions and warnings

  • Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are not up-to-date on mammograms and gynaecological evaluations.
  • Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners or any hormone replacement therapy.
  • Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a liver disorder or a history of hormonal or gynaecological disease.
  • Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms worsen.

Contra-indications

Do not use if you have or had breast cancer or tumours or a predisposition to breast cancer, as indicated by an abnormal mammogram or biopsy, or a family member with breast cancer.

Known adverse reactions

Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if new symptoms develops such as breast pain, a recurrence of menstruation, uterine spotting or liver-related symptoms (e.g. abdominal pain, jaundice, dark urine).

Dosage form: Capsule, hard. Route: Oral.

Health Canada licence record

Evidence, in context.

Three dimensions are recorded separately. One label does not replace the others.

Study type
Clinical trials, systematic reviews, observational studies, mechanistic and preclinical research address different questions.
Relevance to the product
Distinguish finished-product evidence from ingredient evidence and mechanistic relevance. Check the tested formulation, dose and population.
Quality and limitations
Read the sample size, design, duration, population relevance, limitations, and funding or conflicts where available. A study type alone is not a quality rating.

The current S-EQUOL PLUS examples are selected studies, not a complete systematic review. Formal risk-of-bias assessments have not been completed. Missing disclosures are marked in the individual records.

03

Quality

Illustrative milky-white capsule in a shallow recess in a seamless white surface.

Product information

S-EQUOL PLUS · EquoPro
Health Canada product licence

May reduce severe and frequent menopausal symptoms (such as hot flashes and/or night sweats).

Read the full product information, including directions, duration of use, cautions and warnings.


View Health Canada record ↗
S-equol · 10 mg per capsule
Source: synthetic S-equol. The formula provides S-equol directly.
Genistein · 16.7 mg AIE per capsule
Source: Glycine max (soybean) seed. AIE means aglycone isoflavone equivalents.

These are the medicinal ingredients. Consult the product label for the full ingredient list and directions.

S-equol and Genistein are listed separately. This product should not be described as soy-free.

A laboratory report describes the sample and tests identified in that report. It is different from a clinical study of a product’s effects.

Product and batch
Match the product name and batch number. Check whether the sample is a finished product or an ingredient.
Laboratory and methods
Read the laboratory name, report date and methods used.
Results in context
Read each result with its units and stated limits. The report’s scope determines what can be concluded.

No batch-specific report is available to view here yet.

A product licence and a batch test answer different questions. Neither should be presented as a guarantee of an individual’s response.

S-EQUOL PLUS is the product example shown here. Product licences and batch records are specific to each product.

Licensed product information

NPN 80143622 · EquoPro / S-EQUOL PLUS

Recommended use or purpose

May reduce severe and frequent menopausal symptoms (such as hot flashes and/or night sweats).

Medicinal ingredients per capsule

  • S-Equol — 10 mg. Source: S-Equol (Synthetic).
  • Genistein — 16.7 mg AIE. Source: Glycine max — Seed.

Recommended dose

Menopausal and postmenopausal women (18 years and over): 1 capsule, 1 time per day.

Take a few hours before or after taking other medications or health products.

Recommended duration of use

Ask a health care practitioner/health care provider/health care professional/doctor/physician for use beyond 1 year.

Use for at least 2 weeks to see beneficial effects.

Cautions and warnings

  • Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are not up-to-date on mammograms and gynaecological evaluations.
  • Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners or any hormone replacement therapy.
  • Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a liver disorder or a history of hormonal or gynaecological disease.
  • Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms worsen.

Contra-indications

Do not use if you have or had breast cancer or tumours or a predisposition to breast cancer, as indicated by an abnormal mammogram or biopsy, or a family member with breast cancer.

Known adverse reactions

Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if new symptoms develops such as breast pain, a recurrence of menstruation, uterine spotting or liver-related symptoms (e.g. abdominal pain, jaundice, dark urine).

Dosage form: Capsule, hard. Route: Oral.

Health Canada licence record

Your cart.

Your cart is empty.

Explore products

View full cart →